The European Union has recommended Xeloda be used to treat early colon cancer.
Patients should be treated with the drug, manufactured by Roche Holding AG, alongside oxaliplatin (Eloxatin), following surgery for the cancer, an EU committee recommended.
Xeloda is already approved for a variety of treatments and marketed in over 100 countries, with total sales of 1.3 billion Swiss francs in 2009.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey (CINJ) are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients. CINJ is a Center...
Patients With Advanced Kidney Cancer: Switching To Metronomic Therapy Could Offer New Treatment Option
Medical News Today
Article Date: 16 Feb 2010 - 0:00 PST
An article published Online First in The Lancet Oncology reports that a new multi-targeted "chemo-switch" drug regimen shows promising anti-tumour activity with manageable side effects in patients with metastatic renal-cell carcinoma (RCC). This is a disease with few treatment options. The treatment...
Tumors were downstaged in most patients following chemo-surgery regimen, researchers say
TUESDAY, Jan. 26 (HealthDay News) -- An intensive treatment strategy shows promise against locally advanced rectal cancer.
The phase 2 study included 105 patients with poor-risk rectal cancer, meaning they have a high likelihood of disease recurrence and poor survival odds despite receiving standard chemotherapy and optimum surgery.
A colon cancer drug has boosted overall survival in heavily pre-treated patients with advanced metastatic colon cancer, it has been claimed.
Patients receiving the drug KRX-0401, or perifosine, showed more than 60% improvement in overall survival and showed statistically significant advantage for time to progression, when compared with a dummy drug, said Keryx Biopharmaceuticals.
